Amarin Corp PLC

Amarin’s latest equity‑compensation move: new RSU grants, ownership shifts and a robust internal governance strategy aimed at rewarding key talent and driving biotech innovation for cardiovascular therapeutics.

Amarin Corp PLC’s latest SEC Form 4 shows a senior officer’s share hike and RSU grant, underscoring leadership confidence in its cardiovascular drug pipeline and long‑term strategy.

Amarin Corp. exec ups stake to 6,000+ shares, shifts ADS ratio, and exercises RSUs—insight into biotech equity moves that could influence investor views.

Amarin Corporation PLC’s surge on the Frankfurt Stock Exchange underscores its growing promise in cardiovascular therapeutics, driven by a robust pipeline, key partnerships, and strong investor confidence.

Amarin Corporation PLC’s upcoming Q4/2025 results reveal a recovering but volatile stock, spotlighting its cardiovascular drug pipeline and investor hopes.

Amarin’s stock lingers at €7.08 amid a pending US Supreme Court “skinny‑label” patent hearing that could reshape its future.

Amarin faces a Supreme Court patent battle over its “skinny label” strategy—will the ruling protect Vascepa’s exclusivity and reshape biotech patent law?

Amarin’s upcoming Supreme Court case on its “skinny‑label” patent could reshape the biotech market and its 12.90 EUR stock price, offering investors new insights.

Amarin’s latest REDUCE‑IT data confirms icosapent ethyl’s heart‑protective benefits, bolstering its financial outlook and attracting investors amid market volatility.

Amarin’s Q3 2025 results and AHA presentation confirm its cardiovascular therapy’s strength, while stock stays mid‑range, hinting at recovery potential.